causes, myocardial infarction, and stroke in high-risk patients. N. Engl. J. Med., 342:145, 2000.
Ishani, A., Weinhandl, E., Zhao, Z. et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol., 45:391–399, 2005.
Khan, M. Gabriel ACE Inhibitors in Cardiac Drug Therapy, sixth edition. W.B. Saunders, Philadelphia, 2003.
Munzel, T., and Keaney, J.F. Are ACE inhibitors a ‘‘magic bullet’’ against oxidative stress? Circulation, 104:1571–1574, 2001.
Parving, H.-H., Lenhert, H., Brochner-Mortensen, J. et al. for the irbesartan in patients with type II diabetes and microalbuminuria study group: The effect of irbesartan on the development of diabetic nephropathy in patients with type II diabetes. N. Engl. J. Med., 345:870, 2001.
Pitt, B., Poole-Wilson, P.A., Segal, R. et al. ELITE II — effect of losartan compared with captopril on mortality on patients with symptomatic heart failure: Randomized trial. The Losartan Heart Failure Study. Lancet, 255:1582, 2000.
Wachtell, K., Lehto, M., Gerdts, E. et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. J. Am. Coll. Cardiol., 45:712–719, 2005.

Страницы: 1 | 2